Cargando…

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Mar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sweeney, Sedona, Berry, Catherine, Kazounis, Emil, Motta, Ilaria, Vassall, Anna, Dodd, Matthew, Fielding, Katherine, Nyang’wa, Bern-Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022130/ https://www.ncbi.nlm.nih.gov/pubmed/36962909 http://dx.doi.org/10.1371/journal.pgph.0001337

Ejemplares similares

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
por: Berry, Catherine, et al.
Publicado: (2022)

Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO
por: Stringer, Beverley, et al.
Publicado: (2021)

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
por: Sweeney, Sedona, et al.
Publicado: (2020)

Population pharmacokinetics and pharmacodynamics of investigational regimens’ drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial
por: Nyang'wa, Bern-Thomas, et al.
Publicado: (2021)

Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in Uzbekistan
por: Wharton-Smith, Alexandra, et al.
Publicado: (2021)

Association of BMI Category Change with TB Treatment Mortality in HIV-Positive Smear-Negative and Extrapulmonary TB Patients in Myanmar and Zimbabwe
por: Benova, Lenka, et al.
Publicado: (2012)

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
por: du Cros, Philipp, et al.
Publicado: (2021)

The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa
por: Mudzengi, Don, et al.
Publicado: (2017)

Examining Approaches to Estimate the Prevalence of Catastrophic Costs Due to Tuberculosis from Small-Scale Studies in South Africa
por: Sweeney, Sedona, et al.
Publicado: (2020)

Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
por: Ciza, François, et al.
Publicado: (2020)

Does integration of HIV and SRH services achieve economies of scale and scope in practice? A cost function analysis of the Integra Initiative
por: Obure, Carol Dayo, et al.
Publicado: (2016)

TB research requires strong protections, innovation, and increased funding in response to COVID-19
por: Nyang’wa, B. T., et al.
Publicado: (2021)

Measuring income for catastrophic cost estimates: Limitations and policy implications of current approaches
por: Sweeney, Sedona, et al.
Publicado: (2018)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa
por: Knight, Gwenan M., et al.
Publicado: (2015)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
por: Decroo, Tom, et al.
Publicado: (2020)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

Evaluation of a medication monitor-based treatment strategy for drug-sensitive tuberculosis patients in China: study protocol for a cluster randomised controlled trial
por: Lewis, James J., et al.
Publicado: (2018)

The health system burden of chronic disease care: an estimation of provider costs of selected chronic diseases in Uganda
por: Settumba, Stella Nalukwago, et al.
Publicado: (2015)

A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology
por: Cunnama, Lucy, et al.
Publicado: (2020)

Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial
por: Liu, Xiaoqiu, et al.
Publicado: (2023)

Correction to: A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology
por: Cunnama, Lucy, et al.
Publicado: (2020)

Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
por: Rosu, Laura, et al.
Publicado: (2020)

The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
por: Lin, Huang-Shen, et al.
Publicado: (2016)

Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens
por: Kusmiati, Tutik, et al.
Publicado: (2022)

Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
por: Zhang, Zehua, et al.
Publicado: (2014)

Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria
por: Bada, Florence O., et al.
Publicado: (2020)

Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation
por: Vassall, Anna, et al.
Publicado: (2017)

Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin
por: Mankhatitham, W, et al.
Publicado: (2010)

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
por: Goodall, Ruth L, et al.
Publicado: (2022)

Correction: Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria
por: Bada, Florence O., et al.
Publicado: (2021)

Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
por: Cai, Xingshan, et al.
Publicado: (2022)

Rifampicin for Continuation Phase Tuberculosis Treatment in Uganda: A Cost-Effectiveness Analysis
por: Manabe, Yukari C., et al.
Publicado: (2012)

Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis
por: Khaparde, Sunil, et al.
Publicado: (2017)

An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study
por: Surey, J., et al.
Publicado: (2021)

Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Dooley, Kelly E., et al.
Publicado: (2020)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

An overview of the new rifampicin-resistant tuberculosis regimens available at decentralised drug-resistant tuberculosis sites for persons older than six years
por: Muller, Madeleine
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0u53abfdq62t6kiilbh4khvuua